b.

baseimmune.

data-driven vaccine design platform 

About Us

Baseimmune was founded in 2018 as a discovery phase start-up in the antigen discovery and vaccine development field. In October that year, baseimmunes innovative proposal to design antigens against emerging and challenging pathogens was selected to join the accelerator program at the KQ lab cohort 2. 


The company has attracted the attention of major stakeholders and investors in the vaccine field and is currently fundraising its seed round to manufacture the first candidate of the platform. 

b.

Technology

Platform

inputs

Deep

learning

Vaccine

candidates

We utilise deep-learning techniques to monitor pathogen dynamics, predicting forthcoming changes in emerging pathogens and generate vaccines from conserved and functionally critical regions of the pathogens proteome

Baseimmune technologies are based on a data-driven platform for the analysis of pathogen genomics, proteomics, epidemiology and clinical data. Targeted at the faster and cheaper development of effective and safe rationally designed vaccines. 

Team

Ariane C. Gomes, PhD

Phillip Kemlo

Joshua Blight, PhD

Co-founder, CEO

Co-founder, CTO

Co-founder

With talented vaccine experts, scientists, bioinformaticians, and software engineer in the field, baseimmune is committed to translate ‘OMICs’ big-data in real-world solutions. By collaborating with leading institutions and companies and an expert panel of scientific advisors, we hope to develop  vaccines and reduce the burden of infectious diseases in human and animal health.

Pipeline

African Swine Fever:

BSIvet-01 vaccine modality 1:

BSIvet-01 vaccine modality 2:

BSIvet-01 vaccine modality 3:

Design

Preclinical

Phase 1

The baseimmune pipeline currently focuses on major challenges in infectious diseases. We are building a unique pipeline to address veterinary and human threats worldwide.  

Our bespoke antigen discovery platform allied with superior vaccine delivery systems, allow us to fast track the discovery phase of vaccines and move faster to preclinical pipeline. 

News

Contact

info@baseimmune.co.uk

baseimmune

TM